How can clinicians minimize heart and metabolic problems in their patients with prostate cancer? The benefits of androgen-deprivation therapy (ADT) in hormone-sensitive advanced prostate cancer are complicated by related cardiotoxicities and metabolic concerns. Join us on Twitter to discuss how experts identify these problems, use specific protective and management techniques, engage patients, and develop an individualized multidisciplinary treatment plan.
Dipti Gupta, MD, MPH, Program Director, Cardio-Oncology Clinical Research Fellowship Program, Memorial Sloan Kettering Cancer Center (@DrGuptaD); and Alicia Morgans, MD, MPH, Associate Professor of Medicine, Northwestern University Feinberg School of Medicine (@CaPsurvivorship)
Wednesday, Feb. 27, 3:00 p.m. – 3:45 p.m. ET.
How to Join:
Make sure to follow us on Twitter @medpagetoday and join the discussion live on our feed. Use the hashtag #CardioOncoConnect when you tweet; we encourage you to comment, answer questions, ask questions, and react during the chat.
Click here to be taken directly to the chat.
Previous Related Prostate Cancer Cardio-Oncology Connection Articles:
Cardiovascular and Metabolic Effects of Androgen-Deprivation Therapy for Prostate Cancer
Androgen Deprivation Tied to Greater HF Risk in Prostate Cancer Patients
Anticoagulation and Enzalutamide: Caution Over Convenience
Management of Anticoagulation in Patients With Prostate Cancer Receiving Enzalutamide